Research & Literature

Interventions in progressive supranuclear palsy.

Koros C, Stamelou M

Parkinsonism & related disorders 2016; (22 Suppl 1()):S93-5.

Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy.

Owens E, Krecke K, Ahlskog JE, et al.

Parkinsonism & related disorders 2016; (28()):107-11.

Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.

Zanigni S, Calandra-Buonaura G, Manners DN, et al.

NeuroImage. Clinical 2016; (11()):736-742 doi:10.1016/j.nicl.2016.05.016.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, et al.

Movement disorders : official journal of the Movement Disorder Society 2017; (32(7)):995-1005 doi:10.1002/mds.27034.

The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias.

Silsby M, Tweedie-Cullen RY, Murray CR, et al.

European journal of neurology 2017; (24(7)):956-965 doi:10.1111/ene.13314.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, et al.

The Lancet. Neurology 2017; (16(7)):552-563 doi:10.1016/S1474-4422(17)30157-6.

'Hummingbird' Sign in a Patient with Guam Parkinsonism-Dementia Complex.

Yeo T, Tan LC

Journal of movement disorders 2017; (10(3)):145-148 doi:10.14802/jmd.17025.

Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy.

Pilotto A, Gazzina S, Benussi A, et al.

Neuro-degenerative diseases 2017; (17(6)):286-291 doi:10.1159/000479110.

Brain gray matter abnormalities in progressive supranuclear palsy revisited.

Pan P, Liu Y, Zhang Y, et al.

Oncotarget 2017; (8(46)):80941-80955 doi:10.18632/oncotarget.20895.

Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.

van Rumund A, Aerts MB, Esselink RAJ, et al.

BMC neurology 2018; (18(1)):69 doi:10.1186/s12883-018-1072-x.

Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: what's in a phenotype?

Ricciardi L, Edwards MJ, Fasano A, et al.

Journal of the neurological sciences 2018; (390()):84-86 doi:10.1016/j.jns.2018.04.016.

Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.

Quattrone A, Morelli M, Vescio B, et al.

Movement disorders : official journal of the Movement Disorder Society 2019; (34(4)):487-495 doi:10.1002/mds.27621.

Motor, cognitive and behavioral differences in MDS PSP phenotypes.

Picillo M, Cuoco S, Tepedino MF, et al.

Journal of neurology 2019; (266(7)):1727-1735 doi:10.1007/s00415-019-09324-x.

"One line": A method for differential diagnosis of parkinsonian syndromes.

Sako W, Abe T, Haji S, et al.

Acta neurologica Scandinavica 2019; (140(3)):229-235 doi:10.1111/ane.13136.

Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.

Ahn JH, Kim M, Kim JS, et al.

Parkinsonism & related disorders 2019; (66()):80-86 doi:10.1016/j.parkreldis.2019.07.009.

Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

Shoeibi A, Litvan I, Tolosa E, et al.

Parkinsonism & related disorders 2019; (66()):87-93 doi:10.1016/j.parkreldis.2019.07.010.

An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.

Whitwell JL, Stevens CA, Duffy JR, et al.

Movement disorders clinical practice 2019; (6(6)):452-461 doi:10.1002/mdc3.12796.

Exercise and physical activity for people with Progressive Supranuclear Palsy: a systematic review.

Slade SC, Finkelstein DI, McGinley JL, Morris ME

Clinical rehabilitation 2020; (34(1)):23-33 doi:10.1177/0269215519877235.

Alternating flexed-extended posturing in progressive supranuclear palsy.

Ishii N, Mochizuki H

Neurology international 2019; (11(3)):8257 doi:10.4081/ni.2019.8257.

4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Saijo E, Metrick MA, Koga S, et al.

Acta neuropathologica 2020; (139(1)):63-77 doi:10.1007/s00401-019-02080-2.

The Progressive Supranuclear Palsy: Past and Present Aspects.

Parthimos TP, Schulpis KH

Clinical gerontologist 2020; (43(2)):155-180 doi:10.1080/07317115.2019.1694115.

Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia.

Ando S, Kanazawa M, Onodera O

Journal of movement disorders 2020; (13(1)):20-26 doi:10.14802/jmd.19061.

Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules.

Ogawa T, Hatano T, Oyama G, et al.

Movement disorders clinical practice 2020; (7(2)):240-242 doi:10.1002/mdc3.12894.

Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.

VandeVrede L, Dale ML, Fields S, et al.

Movement disorders clinical practice 2020; (7(4)):440-447 doi:10.1002/mdc3.12940.

Reply to: "Brief Clinical Rating Scales Should Not Be Overlooked".

Respondek G, Piot I, Höglinger GU

Movement disorders : official journal of the Movement Disorder Society 2020; (35(10)):1886 doi:10.1002/mds.28273.

Association of PSP phenotypes with survival: A brain-bank study.

Guasp M, Molina-Porcel L, Painous C, et al.

Parkinsonism & related disorders 2021; (84()):77-81 doi:10.1016/j.parkreldis.2021.01.015.

Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting.

Cooperrider J, Bluett B, Jones SE

Clinical parkinsonism & related disorders 2020; (3()):100033 doi:10.1016/j.prdoa.2020.100033.

Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy.

Clark HM, Tosakulwong N, Weigand SD, et al.

Movement disorders : official journal of the Movement Disorder Society 2021; (36(11)):2669-2675 doi:10.1002/mds.28731.

A critical appraisal of tau-targeting therapies for primary and secondary tauopathies.

Imbimbo BP, Ippati S, Watling M, Balducci C

Alzheimer's & dementia : the journal of the Alzheimer's Association 2022; (18(5)):1008-1037 doi:10.1002/alz.12453.

Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.

Bower SM, Weigand SD, Ali F, et al.

Movement disorders clinical practice 2022; (9(2)):212-217 doi:10.1002/mdc3.13396.

Protracted course progressive supranuclear palsy.

Couto B, Martinez-Valbuena I, Lee S, et al.

European journal of neurology 2022; (29(8)):2220-2231 doi:10.1111/ene.15346.

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.

Quattrone A, Bianco MG, Antonini A, et al.

Movement disorders : official journal of the Movement Disorder Society 2022; (37(6)):1272-1281 doi:10.1002/mds.28992.

Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review.

Macedo AC, Mariano LI, Martins MI, et al.

Movement disorders clinical practice 2022; (9(4)):436-445 doi:10.1002/mdc3.13435.

Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies.

Carlos AF, Tosakulwong N, Weigand SD, et al.

Brain communications 2022; (4(3)):fcac108 doi:10.1093/braincomms/fcac108.

Probable progressive supranuclear palsy in a patient with chronic schizophrenia: A case report.

Kita A, Tsuji T, Koh J, et al.

Experimental and therapeutic medicine 2022; (24(1)):484 doi:10.3892/etm.2022.11411.

Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel.

Barer Y, Chodick G, Cohen R, et al.

Brain sciences 2022; (12(9)) doi:10.3390/brainsci12091126.

Development and implementation of an aspiration pneumonia cause investigation algorithm.

Yoshimatsu Y, Tobino K, Ortega O, et al.

The clinical respiratory journal 2023; (17(1)):20-28 doi:10.1111/crj.13557.

Pathomechanisms of cognitive impairment in progressive supranuclear palsy.

Jellinger KA

Journal of neural transmission (Vienna, Austria : 1996) 2023; (130(4)):481-493 doi:10.1007/s00702-023-02613-w.

Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings.

Mena AM, Chen R, Graff-Guerrero A, et al.

Movement disorders clinical practice 2023; (10(12)):1725-1737 doi:10.1002/mdc3.13885.

Physiotherapy case reports on three people with progressive supranuclear palsy.

Mateus M, Castro Caldas A

Frontiers in aging neuroscience 2023; (15()):1294293 doi:10.3389/fnagi.2023.1294293.

Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome.

Parmera JB, de Godoi Carneiro C, de Almeida IJ, et al.

Movement disorders clinical practice 2024; (11(3)):238-247 doi:10.1002/mdc3.13959.

Predicting Disability in Progressive Supranuclear Palsy Using Bedside Frontal-Lobe Signs.

Ruiz-Barrio I, Horta-Barba A, Aracil-Bolaños I, et al.

Movement disorders clinical practice 2024; (11(3)):248-256 doi:10.1002/mdc3.13958.

Aspiration Pneumonia.

Pan D, Chung S, Nielsen E, Niederman MS

Seminars in respiratory and critical care medicine 2024; (45(2)):237-245 doi:10.1055/s-0043-1777772.

Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.

Nasri A, Sghaier I, Neji A, et al.

Journal of movement disorders 2024; (17(2)):158-170 doi:10.14802/jmd.23178.

The role of nurses for patients with Parkinson's disease at home: a scoping review.

Fujita T, Iwaki M, Hatono Y

BMC nursing 2024; (23(1)):318 doi:10.1186/s12912-024-01931-y.

Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies.

DeRosier F, Hibbs C, Alessi K, et al.

Disease-a-month : DM 2024; (70(8)):101753 doi:10.1016/j.disamonth.2024.101753.

DNA methylation patterns in the frontal lobe white matter of multiple system atrophy, Parkinson's disease, and progressive supranuclear palsy: a cross-comparative investigation.

Murthy M, Fodder K, Miki Y, et al.

Acta neuropathologica 2024; (148(1)):4 doi:10.1007/s00401-024-02764-4.

Long-standing preservation of levodopa response in progressive supranuclear palsy.

Sano T, Mizutani M, Ishihara T, et al.

Journal of the neurological sciences 2024; (466()):123203 doi:10.1016/j.jns.2024.123203.

Self-Management Systems for Patients and Clinicians in Parkinson's Disease Care: A Scoping Review.

Boege S, Milne-Ives M, Ananthakrishnan A, et al.

Journal of Parkinson's disease 2024; (14(7)):1387-1404 doi:10.3233/JPD-240137.

Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

Ye L, Sani SS, Veith Sanches L, et al.

Brain sciences 2024; (14(10)) doi:10.3390/brainsci14100991.

Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.

Slemann L, Gnörich J, Hummel S, et al.

Acta neuropathologica 2024; (148(1)):70 doi:10.1007/s00401-024-02834-7.

Rapid Cognitive Deterioration in Progressive Supranuclear Palsy: A 1-Year Follow-Up Study.

Li XY, Yang YJ, Jiao FY, et al.

Movement disorders clinical practice 2025; (12(4)):475-483 doi:10.1002/mdc3.14315.

A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.

Dam T, Yang L, Gillis C, et al.

Nature communications 2025; (16(1)):414 doi:10.1038/s41467-024-55442-0.

Performance of a Two-Week Rehabilitation Improves Motor Function in Inpatients with Progressive Supranuclear Palsy: A Pre-Post Study.

Matsuda N, Takamatsu Y, Sawada M, Aiba I

Brain sciences 2025; (15(1)) doi:10.3390/brainsci15010088.

Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.

Marchand F, Blaise AS, Defebvre L, et al.

Journal of Parkinson's disease 2024; (14(8)):1652-1658 doi:10.1177/1877718X241291996.

Tongue strength in progressive supranuclear palsy.

Clark HM, Stierwalt JA, Meade G, et al.

Parkinsonism & related disorders 2025; (135()):107839 doi:10.1016/j.parkreldis.2025.107839.

Head position control strategies in progressive Supranuclear Palsy versus Idiopathic Parkinson's Disease during dynamic-on-static platform tilt.

Kammermeier S, Maierbeck K, Dietrich L, et al.

Frontiers in neurology 2024; (15()):1477493 doi:10.3389/fneur.2024.1477493.

The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.

Morales-Rivero A, Garcia-Cordero I, Khoja A, et al.

European journal of neurology 2025; (32(6)):e70248 doi:10.1111/ene.70248.

Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.

Garcia-Cordero I, Vargas-Gonzalez JC, Hadian M, et al.

Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21(7)):e70485 doi:10.1002/alz.70485.

Progressive Supranuclear Palsy and Corticobasal Syndrome.

McFarland NR

Continuum (Minneapolis, Minn.) 2025; (31(4)):1023-1049 doi:10.1212/cont.0000000000001607.

Differences in neuropsychological performance across clinical variants of progressive supranuclear palsy.

Boots EA, Weigand SD, Pham NTT, et al.

Journal of the International Neuropsychological Society : JINS 2025; (31(5-6)):384-395 doi:10.1017/S1355617725101215.

Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale.

Shen Q, Zhao YX, Tang G, et al.

Journal of neural transmission (Vienna, Austria : 1996) 2025; doi:10.1007/s00702-025-03031-w.